| Patient characteristics . | Number (N = 89) . |
|---|---|
| Age, years | 65 (Range 15–81) |
| Gender, male | 72 (80.9%) |
| ASA classification | |
| I | 11 (12.5%) |
| II | 40 (44.9%) |
| III | 36 (40.4%) |
| IV | 2 (2.2%) |
| Tumour histology | |
| Adenocarcinoma | 78 (87.6%) |
| Squamous cell carcinoma | 11 (12.4%) |
| Tumour location | |
| Mid esophagus | 6 (6.7%) |
| Distal esophagus | 72 (80.9%) |
| Gastroesophageal junction | 11 (12.4%) |
| Clinical T staging | |
| T1 | 4 (4.5%) |
| T2 | 24 (26.9%) |
| T3 | 56 (62.9%) |
| T4 | 5 (5.6%) |
| Neoadjuvant therapy | |
| Chemotherapy alone (FLOT) | 8 (8.9%) |
| Chemoradiotherapy (CROSS) | 74 (83.1%) |
| None | 7 (8%) |
| Patient characteristics . | Number (N = 89) . |
|---|---|
| Age, years | 65 (Range 15–81) |
| Gender, male | 72 (80.9%) |
| ASA classification | |
| I | 11 (12.5%) |
| II | 40 (44.9%) |
| III | 36 (40.4%) |
| IV | 2 (2.2%) |
| Tumour histology | |
| Adenocarcinoma | 78 (87.6%) |
| Squamous cell carcinoma | 11 (12.4%) |
| Tumour location | |
| Mid esophagus | 6 (6.7%) |
| Distal esophagus | 72 (80.9%) |
| Gastroesophageal junction | 11 (12.4%) |
| Clinical T staging | |
| T1 | 4 (4.5%) |
| T2 | 24 (26.9%) |
| T3 | 56 (62.9%) |
| T4 | 5 (5.6%) |
| Neoadjuvant therapy | |
| Chemotherapy alone (FLOT) | 8 (8.9%) |
| Chemoradiotherapy (CROSS) | 74 (83.1%) |
| None | 7 (8%) |
| Patient characteristics . | Number (N = 89) . |
|---|---|
| Age, years | 65 (Range 15–81) |
| Gender, male | 72 (80.9%) |
| ASA classification | |
| I | 11 (12.5%) |
| II | 40 (44.9%) |
| III | 36 (40.4%) |
| IV | 2 (2.2%) |
| Tumour histology | |
| Adenocarcinoma | 78 (87.6%) |
| Squamous cell carcinoma | 11 (12.4%) |
| Tumour location | |
| Mid esophagus | 6 (6.7%) |
| Distal esophagus | 72 (80.9%) |
| Gastroesophageal junction | 11 (12.4%) |
| Clinical T staging | |
| T1 | 4 (4.5%) |
| T2 | 24 (26.9%) |
| T3 | 56 (62.9%) |
| T4 | 5 (5.6%) |
| Neoadjuvant therapy | |
| Chemotherapy alone (FLOT) | 8 (8.9%) |
| Chemoradiotherapy (CROSS) | 74 (83.1%) |
| None | 7 (8%) |
| Patient characteristics . | Number (N = 89) . |
|---|---|
| Age, years | 65 (Range 15–81) |
| Gender, male | 72 (80.9%) |
| ASA classification | |
| I | 11 (12.5%) |
| II | 40 (44.9%) |
| III | 36 (40.4%) |
| IV | 2 (2.2%) |
| Tumour histology | |
| Adenocarcinoma | 78 (87.6%) |
| Squamous cell carcinoma | 11 (12.4%) |
| Tumour location | |
| Mid esophagus | 6 (6.7%) |
| Distal esophagus | 72 (80.9%) |
| Gastroesophageal junction | 11 (12.4%) |
| Clinical T staging | |
| T1 | 4 (4.5%) |
| T2 | 24 (26.9%) |
| T3 | 56 (62.9%) |
| T4 | 5 (5.6%) |
| Neoadjuvant therapy | |
| Chemotherapy alone (FLOT) | 8 (8.9%) |
| Chemoradiotherapy (CROSS) | 74 (83.1%) |
| None | 7 (8%) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
